抄録
Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.
本文言語 | 英語 |
---|---|
ページ(範囲) | 118-119 |
ページ数 | 2 |
ジャーナル | Clinical and Experimental Neuroimmunology |
巻 | 6 |
号 | 2 |
DOI | |
出版ステータス | 出版済み - 5月 1 2015 |
!!!All Science Journal Classification (ASJC) codes
- 神経科学(その他)
- 免疫学
- 免疫学および微生物学(その他)
- 臨床神経学